There are several candidates of protein or microRNA-based biomarkers for GBM, such as glial fibrillary acidic protein (GFAP) [10,11,12], miR-340 [13], miR-185 [14], and miR-210 [15]; however, their values for prognostic prediction or disease progression monitoring remain unproven in clinical trials. This evidence concerns the gene GFAP and glioblastoma.